Results 81 to 90 of about 3,003 (174)

Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant

, 2000
In a patient with heparin-induced thrombocytopenia II and impaired renal function, anticoagulation during cardiopulmonary bypass was successfully performed by the use of unfractionated heparin and the platelet glycoprotein IIb/IIIa inhibitor tirofiban ...
Kuppe, Hermann, Koster, Andreas, Hetzer, Roland, Loebe, Matthias, Mertzlufft, Fritz   +4 more
core   +1 more source

[Update on the pharmacological treatment of unstable angina.]

, 1996
The combined death/infarct rate in the weeks following unstable angina ranges from 10 to 40 %. Aspirin and GP Ilb/IIIa antagonists reduce the mortality and morbidity, which has not been demonstrated with heparin.
Col, Jacques
core  

Inhalable biomimetic nanomotor for pulmonary thrombus therapy

The complications of pulmonary thrombosis caused by the coronavirus pneumonia have created an unprecedented clinical need for efficient targeted therapy of pulmonary thrombosis.
Han, Heyou, Long, Yuying, Li, Shuting, Zhao, Yanli, Zhang, Kai   +4 more
core   +1 more source

College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.

Archives of pathology & laboratory medicine, 1998
To review the role of the laboratory in monitoring therapy with low-molecular-weight heparin, danaparoid, hirudin, and argatroban, as reflected in the medical literature and the consensus opinion of recognized experts in the field.Review of the medical literature and current clinical practice by a panel of 6 international experts in the field of ...
M, Laposata, D, Green, E M, Van Cott, T W, Barrowcliffe, S H, Goodnight, R C, Sosolik   +5 more
openaire   +1 more source

Local (Malaysian) Leech as Alternative Healing Treatment and an Islamic Perspective [PDF]

, 2016
The therapy is known from the time of extreme antiquity, dating back more than 2,500 years ago and still being practiced nowadays. This fact testifies to its efficiency in various health problems.
ZULHISYAM, A. K., LEE, S. W., WAN YUSOFF, W. S., JAMALUDIN, M. H., AHMAD ZAKI AMIRUDDIN   +4 more
core  

Is the ecarin clotting time (ECT) a valid monitoring parameter for r-hirudin-based anticoagulation in continuous renal replacement therapy? [PDF]

Critical Care, 2000
v Heymann, C, Vargas Hein, O, Ziemer, S, Sinha, P, Schröder, T, Nissen, J, Lips, M, Spies, C   +7 more
openaire   +1 more source

A Biomimetic Macrophage-Membrane-Fused Liposomal System Loaded with GVs-HV Recombinant Plasmid for Targeted Anti-Atherosclerosis Therapy. [PDF]

Pharmaceutics
Zhang Y, Gu W, Yu K, Chen Q, Wang H, Wei Y, Zheng H, Zheng H, Liu L, Li F.   +9 more
europepmc   +1 more source

Hirudin suppresses hematogenous metastasis by targeting desmosome junction transition in circulating tumor cell clusters via HIF-1α-DSG2 signaling. [PDF]

Exp Mol Med
Zou J, Shi J, Chen Q, Zhu Z, Hu T, Zhang Z, Pan Z, Xu F, Zhu Y, Wu Y, Zhao Y, Wang A, Lu Y, Pan Y, Chen W.   +14 more
europepmc   +1 more source

On a quest for fingerprints of crystalglobulinemia on platelets and endothelium. [PDF]

Blood Vessel Thromb Hemost
Gkalea V, Nikolaou PE, Pappas T, Papadimou A, Courraud J, Tsoumani M, Margiola MS, Voumvouraki M, Malandrakis P, Gakiopoulou C, Sfikakis PP, Matsouka C, Andreadou I, Fotiou D, Kastritis E, Dimopoulos AM.   +15 more
europepmc   +1 more source

Platelet deposition and thrombosis in arterial stents: Effect of hirudin compared with heparin plus antiplatelet therapy

Journal of the American College of Cardiology, 1990
Garratt, Kirk N., Heras, Magda, Holmes Jr., David R., Roubin, Gary S., Chesebro, James H.   +4 more
openaire   +1 more source